Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Cervarix Co-administered with Havrix in Adolescents
NCT02082639Phase 3Withdrawn
- Sponsor
- GSK
- Start
- Feb 2015
- Primary completion
- Aug 2015
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, open-label trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection (3 arms), sponsored by GSK. Primary endpoints: Anti-HPV-16/18 seroconversion status at Month 7, Anti-HPV-16/18 antibody titres at Month 7 and 2 more. Planned start Feb 2015; status: withdrawn.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT02082639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02082639.